Cosmetics Brands Urged To Audit Green Claims As EU EmpCo Rules Kick In
Regulatory consultant Bethany Dean of Taylored Consultancy outlines six steps cosmetics companies should take to comply with the EU’s new EmpCo greenwashing rules, including how to assess risky claims, substantiate environmental benefits and address non-compliant packaging already on the market.
HBW Insight - November 11, 2026

Oyster Therapeutics Raises $60m To Target Alzheimer’s With Protein Degraders
UK-headquartered biotech believes its new generation of protein degraders can target tau and other disease-causing proteins in the central nervous system.
Scrip - November 11, 2026

Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
Lilly’s stock hit a 52-week high while Alnylam’s hit a 52-week low when both reported third-quarter results on Oct. 29. Both depend heavily on a dominant franchise.
Scrip - November 11, 2026

Volume Growth Is ‘Key Measure’ For Opella CGO Alberto Hernandez
Exclusive Interview: Opella chief growth officer Alberto Hernandez says the company is growing in volume while most rivals rely on price. He puts this achievement down to prevention-led brand extensions, such as Dulcolax gummies, and to Opella being wherever consumers shop.
HBW Insight - November 11, 2026

‘Warning Shot’: Medtech’s IT Breaches Could Hand Hackers A Blueprint For Device Attacks
The cyberattacks that hit Stryker and Boston Scientific this year stopped short of devices. A security executive warns that what intruders learn inside corporate networks could one day be turned on products in hospitals.
Medtech Insight - November 11, 2026

‘We Want Partners Who Can Grow With Us’ – CinnaGen Chair Hamedifar On The Firm’s Plans For Europe
After receiving an EU approval for its Zandoriah teriparatide biosimilar earlier this year, Iran’s CinnaGen is looking to build up a broader portfolio while also seeking European marketing partners who can “grow with us beyond one product,” chairperson Haleh Hamedifar tells Generics Bulletin.
Generics Bulletin - November 11, 2026

Beam Eyes Risto-Cel BLA As Early As Year-End After Positive Sickle Cell Data
Beam's risto-cel hits primary efficacy endpoint of freedom from severe VOCs in the Phase I/II BEACON study, setting up a potential BLA filing with the US Food and Drug Administration.
Scrip - November 11, 2026

EU Provides More Breakthrough Device Details As Pilot Enters Next Phase
Six devices have been successfully assessed under the program, but the European Commission is taking a cautious approach to expansion.
Medtech Insight - November 11, 2026

TikTok Isn’t Just Videos And Isn’t Just For Teenagers
TikTok tells IQVIA Consumer Health's Global Brand Growth Forum in Paris that firms are already seeing measurable sales gains on a platform many still dismiss as a teenage video app.
HBW Insight - November 11, 2026

Bio-Thera Claims First Simponi Biosimilar Approval In China
China’s NMPA has approved Bio-Thera’s golimumab biosimilar Ashuli for rheumatoid arthritis and ankylosing spondylitis, which the firm says is the country’s first rival to J&J’s Simponi.
Generics Bulletin - November 11, 2026

ACR 2026: Can ImmuneOnco‘s Bispecific Take On Roche’s Gazyva In SLE?
In a major update to an ongoing Phase Ib program, ImmuneOnco's amulirafusp ? showed an up to 90.9% SRI-4 response rate at 24 weeks in Chinese patients with active systemic lupus erythematosus.
Scrip - November 11, 2026

Headline Risk, Bottom-Line Risk: Pharma’s Guide To Democratic Control Of Congress
Oversight of the Most Favored Nation deals is coming, but the larger financial stakes for the pharma industry in the next Congress are a Democratic push for Medicare pricing expansion as well as risks to FDA stability if user fee reauthorization becomes a political football.
In Vivo - November 11, 2026

Divamics Targeting Differentiation In Application Of AI To Drug Design
Executives from Chinese AI-driven biotech Divamics sit down with Scrip to talk about the rationale behind the founding of the company, its in-house AI platforms, R&D and business strategies and approach to differentiation in a fast-changing area.
Scrip - November 11, 2026

California’s DTSC Flags Ortho-Phthalates In Children’s Products
Ortho-phthalates could be next in line for regulatory action by California’s Department of Toxic Substances Control, which also plans to focus on five product categories in the coming years, including personal care.
HBW Insight - November 11, 2026

FDA Finalizes Guidance On Validating Emergency Tests For The Next Pandemic
The FDA has finalized guidance on validating diagnostic tests for emerging pathogens during a declared emergency. It lets developers send some data after submission and use synthetic samples early in an outbreak. It also covers study design, home-use testing and more.
Medtech Insight - November 11, 2026